An Open Label, Prospective, Observational, Non-interventional Study of Bevacizumab in Combination With Interferon Alpha-2a for the First-line Treatment of Patients With Advanced and/or Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2a (Primary)
- Indications Renal cancer
- Focus Adverse reactions
- Sponsors Roche
- 16 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Sep 2011 Planned end date changed from 1 Dec 2014 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 14 May 2011 New trial record